Dakota BioWorx’s Post

Come and talk to us about your plans and challenges in drug development #pharma #drugdevelopment

Beyond excited to share the news that #CreyonBio is presenting clinical data for AI-assisted antisense oligonucleotide drug discovery at the ASGCT meeting! It's been an incredible journey, and I'm extremely fortunate and proud to be a part of such an outstanding team. Thank you to everyone who has supported us along the way! 🌟 #ASGCT #BiotechInnovation #DrugDiscovery #CreyonBio Snippet from the Press Release:- ".....Within one year of project initiation in partnership with The TNPO2 Foundation, Creyon developed a novel allele-selective Locked Nucleic Acid (LNA) treatment candidate for an ultra-rare and severe neurological disease caused by a single nucleotide variant in the Transportin-2 (TNPO2) receptor, and an investigator-initiated clinical trial received approval to dose a patient........This treatment has been well-tolerated with no increase in inflammatory markers in the cerebrospinal fluid (CSF) or adverse changes on brain MRI scans. Notably, the patient experienced reduced seizure frequency after the second dose and regained developmental milestones including rolling, sustained attention and gaining novel skills such as tripod sitting and responsive babbling after the third dose......" https://lnkd.in/g3TA7FH9

While the Christmas may be over, we’re still in the giving spirit. As we step into 2025, we have a special gift for you, our valued customers. As always, this year we're pledging to support the iPSC community, helping researchers to unlock the benefits of iPSC technology for better human disease models. As part of this pledge, we're making it easier and more affordable to access and use market-leading iPSC technology. That includes those new to iPSCs, researchers already engaged with iPSC technology, and groups looking to scale up in size and complexity. At Axol, we believe in the power of partnership and staying committed to providing high-quality products at the best value. As a token of appreciation for your continued trust and support, this is our gift to you — a promise of no price rises for the entire year. Whether you're looking to use iPSCs for the first time or want to scale up your in vitro projects, let us know what we can do to help by contacting us at operations@axolbio.com. We look forward to continuing our journey together in the new year and beyond. #iPSCs #StemCells #DrugDiscovery #Biotech #NewYear2025 #CustomerAppreciation #Manufacturing #NoPriceIncreases

While the Christmas may be over, we’re still in the giving spirit. As we step into 2025, we have a special gift for you, our valued customers. As always, this year we're pledging to support the iPSC community, helping researchers to unlock the benefits of iPSC technology for better human disease models. As part of this pledge, we're making it easier and more affordable to access and use market-leading iPSC technology. That includes those new to iPSCs, researchers already engaged with iPSC technology, and groups looking to scale up in size and complexity. At Axol, we believe in the power of partnership and staying committed to providing high-quality products at the best value. As a token of appreciation for your continued trust and support, this is our gift to you — a promise of no price rises for the entire year. Whether you're looking to use iPSCs for the first time or want to scale up your in vitro projects, let us know what we can do to help by contacting us at operations@axolbio.com. We look forward to continuing our journey together in the new year and beyond. #iPSCs #StemCells #DrugDiscovery #Biotech #NewYear2025 #CustomerAppreciation #Manufacturing #NoPriceIncreases

While the Christmas may be over, we’re still in the giving spirit. As we step into 2025, we have a special gift for you, our valued customers. As always, this year we're pledging to support the iPSC community, helping researchers to unlock the benefits of iPSC technology for better human disease models. As part of this pledge, we're making it easier and more affordable to access and use market-leading iPSC technology. That includes those new to iPSCs, researchers already engaged with iPSC technology, and groups looking to scale up in size and complexity. At Axol, we believe in the power of partnership and staying committed to providing high-quality products at the best value. As a token of appreciation for your continued trust and support, this is our gift to you — a promise of no price rises for the entire year. Whether you're looking to use iPSCs for the first time or want to scale up your in vitro projects, let us know what we can do to help by contacting us at operations@axolbio.com. We look forward to continuing our journey together in the new year and beyond. #iPSCs #StemCells #DrugDiscovery #Biotech #NewYear2025 #CustomerAppreciation #Manufacturing #NoPriceIncreases

🌟 Did you miss any of our Fierce Biotech 2024 Special Reports? 📖 Explore all 2024 Special Reports now: https://loom.ly/Tu5YVtw From cutting-edge breakthroughs to deep dives into industry trends, Fierce Biotech has been your go-to source for insights this year. Don’t let the year end without catching up on the stories that mattered most. And don’t forget—2025 is just around the corner, and we’ll be back with even more exclusive content to keep you in the know. Stay tuned! Looking for more ways to stay ahead in the industry? Follow Fierce Life Sciences Events for upcoming events, industry news and more. #FierceBiotech #BiotechInsights #SpecialReports

💡💡💡it’s #SAPAGP ‘s pleasure to be a partner with InScienceWeTrust Community to co-organize the #BioVerseWebinar series. Please feel free to let us know what topics you would love to hear in the future by leaving your comment!

If you’ve navigated through the toughest downturn in #biotech history, you’ve proven your mettle. But the challenges for CEOs and boards will only grow in 2025. Delivering results in an uncertain market is the name of the game. ➤ How do you ensure discipline and advance your pipeline to the next inflection point? ➤ How do you experiment with AI and data science to accelerate drug development? ➤ How do you differentiate yourself from peers to find the right investors, partners, and talent? BioCentury Inc. and BioIndustry Association (BIA) convene a special industry roundtable at the 2nd annual CEO and investor dialogue to answer these questions and more. Panelists: ➤ Laura A. Lane, Eli Lilly and Company ➤ Michael Margolis, Oppenheimer & Co. Inc. ➤ Evan Matlin, MTS Health Partners ➤ Chris Sheldon, PhD, GSK ➤ Erica Whittaker, UCB Ventures Moderator: Stephen Hansen, BioCentury Inc. View the agenda and register to join us during #LondonLifeSciencesWeek: https://lnkd.in/gbcVR7m2 If you are a BioCentury subscriber or BIA member, please email conferences@biocentury.com for a registration code to access exclusive member/subscriber pricing. #LLSW2024 #BiotechCommunity #LifeSciences #LondonLifeSciences

Partner Chris Shelley, member of our life sciences sector group, recently took part in the BioFIT Event for 2024 in Lille, the leading European event for early-stage deals and investment rounds in the field of life sciences. Chris moderated a panel titled ‘Navigating a deal structure: Overview, market practices and how to approach’, featuring Guy Hélin (Syngulon), Lilian Alcaraz (Johnson & Johnson Innovation), and Tamar Raz (Hadasit). Key questions discussed by the speakers included the differences between deal structures, how these deal structures vary based on the area of technology or therapeutic indication, and what the key points of a successful deal are. #lifesciences #BioFIT2024 #deals #investment 

📆 Join Camille Samuels of Venrock, Tim Scott of Biocom California, Nina Kjellson of Canaan Partners and Greg Bisconti of JLL for a life sciences #venturecapital outlook webinar. What are the lessons from 2024 and what's in store for 2025? Regardless of fluctuation, venture and other risk capital investments have fueled #biotech innovation and set the groundwork for life sciences industry growth. Both early stage and mature life sciences companies can benefit from the insights shared. Register now >> #JLLLifeSciences #biotechventurecapital